It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

GSK Covid-19 monoclonal treatment shows potential benefit for older patients

Thu 25 February 2021 19:21 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - A phase two clinical study on GlaxoSmithKline's monoclonal antibody treatment against Covid-19 revealed a "potentially important" benefit in reducing respiratory failure in patients aged 70 or older.

Overall, the study, which involved a total of 806 volunteers, showed only a 5% reduction in respiratory failure among all participants dosed with a single dose of the treatment, known as Otilimab, in addition to standard of care, in comparison to those who only received standard of care.

That result was not considered "statistically significant".

Standard of care was defined as anti-viral treatments and corticosteroids.

However, among the 180 patients aged 70 or older, 65.1% of those who received Otilimab and standard of care were alive and free of respiratory failure 28 days after starting their treatment, against 45.9% for those receiving standard of care alone.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast